JACC This Week

In the September 10, 2024, issue of JACC, the study by Dr. Doron Seeker and colleagues investigates alirocumab's impact on cardiovascular outcomes related to triglyceride levels. Despite effectively lowering LDL cholesterol, alirocumab did not show significant clinical benefit through triglyceride reduction, suggesting that its efficacy may be limited in addressing cardiovascular risk associated with elevated triglycerides.

Rasha K. Al-Lamee, MD, PhD, JACC Deputy Editor and Navin K. Kapur MD discuss the work from the Cardiogenic Shock Working Group, which is an academic research consortium comprising ~40 hospitals in the U.S. and internationally.

Aakriti Gupta, MD, FACC, JACC Executive Associate Editor, and Stefan D. Anker, MD, discuss the insights from the RESHAPE-HF2 trial - an eight-year study on the efficacy of transcatheter edge-to-edge repair for mitral valve regurgitation in patients with heart failure.

Khurram Nasir, an Associate Editor at JACC with expertise in cardiovascular care, joins Tor Biering-Sorenson, a medical doctor with advanced public health degrees, to delve into the critical role of influenza vaccines for chronic kidney disease (CKD) patients. They discuss findings from the DANFLU-1 trial, highlighting the potential benefits of high-dose vaccines over standard doses. The conversation underscores the broader health impacts of flu vaccination, particularly in reducing complications in high-risk populations and advocating for increased immunization efforts in underserved communities.

Neha J. Pagidipati, MD, FACC, JACC Associate Editor and Subodh Verma MD, PhD explore a secondary analysis of the SELECT trial, a landmark study investigating the cardiovascular benefits of semaglutide in people with obesity or overweight without diabetes.

Neha J. Pagidipati, MD, FACC, JACC Associate Editor and Mikhail Kosiborod, MD, FACC discuss an exciting secondary analysis of the STEP-HFpEF program, shedding light on the groundbreaking findings related to heart failure and obesity.

Harlan Krumholz, MD, FACC, JACC Editor-in-Chief, and Benjamin M. Scirica, MD, MPH, FACC, discuss the surprising benefits of semaglutide beyond weight loss and cardiovascular health from the SELECT trial, which investigated the effects of semaglutide on COVID-19 outcomes and non-cardiovascular deaths in patients with obesity and cardiovascular disease.

Neha J. Pagidipati, MD, FACC, JACC Associate Editor, and Richard Pratley, MD, discuss insights from the FLOW trial – revealing that semaglutide reduced heart failure events and cardiovascular death by approximately 27%, both in patients with and without prior heart failure.

In the September 3, 2024, issue of JACC, Dr. Valentin Fuster introduces a pivotal study on Brugada syndrome in children and adolescents. This research, led by Dr. Marco Berganti and colleagues, demonstrates how continuous monitoring with implanted loop recorders provides critical insights into arrhythmias and syncope in young patients, highlighting the potential for future AI-driven personalized care in this complex condition.

Dr. Valentin Fuster discusses the Augustus trial's groundbreaking findings on antithrombotic strategies for atrial fibrillation patients post-acute coronary syndrome or PCI. The study reveals that a regimen of apixaban and a P2Y12 inhibitor—without aspirin—offers superior safety and efficacy, challenging traditional triple therapy approaches.